A new experimental drug called CS18 may help break through cancer drug resistance by disabling several of the defenses tumors use to survive treatment. It strengthened existing therapies, restored drug sensitivity in resistant lung cancer cells, and slowed tumor growth in animal models.

Researchers at Baylor College of Medicine have developed an experimental drug called CS18 that may help cancer treatments work against tumors that have become resistant to therapy. The study, published in Science Advances, provides early evidence supporting further investigation of CS18 as a possible future cancer treatment.

“Therapeutic resistance is a main obstacle to achieve effective and durable cancer treatments,” said corresponding author Dr. Weei-Chin Lin, professor of medicine – hematology and oncology and of molecular and cellular biology at Baylor. “While some therapies are effective at the beginning, many patients eventually relapse because cancer cells can activate compensatory and convergent biological pathways that allow them to overcome the toxic effects of therapy, promoting survival.”

https://www.sciencedaily.com/releases/2026/09/260921081112.htm